Douglas Huey Email

Executive Director . PYC Therapeutics

Current Roles

Employees:
78
Revenue:
$12.1M
About
PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC's discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations.
PYC Therapeutics Address
San Diego
California, CA
United States
PYC Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.